04/06/2025
💬 “What excites you most about Cellevate’s journey, and where do you see the company heading?
There are three things that truly excite me. First, our Cellevat3d® nanofiber microcarriers can reduce the cost of viral vector therapy production by up to 70% – a game-changer, considering current treatments can cost up to €1 million per dose. This has the potential to dramatically improve access to life-saving therapies for millions of patients. Second, I’m incredibly proud that we brought our first product to market in under three years – a remarkable team achievement for any biotech company. Lastly, I’m energised by our strategic partnerships with leading pharma companies, CDMOs, and bioprocessing providers. Together, we’re working towards more sustainable, scalable solutions that can reduce costs, improve yields, and ultimately support better, more accessible healthcare.”
In the Life Science Barometer 2025 – Skåne Edition, our CEO Laura Chirica, PhD shares insights on Cellevate’s journey, the challenges of commercialization, and what it takes for life science startups to scale and succeed globally.
📖 Read the full interview in the Life Science Barometer 2025 – Skåne Edition report by Medicon Village (p.23):
https://www.mediconvillage.se/app/uploads/2025/05/Medicon-Village-Life-Science-Barometer-Skane-2025-final-report.pdf
The report, focused mainly on the Southern part of Sweden, Skåne, provides a snapshot of the life science industry outlining the current economic challenges, geopolitical tensions, funding, creating value, patenting, HR outlook and investor perspectives on the current investment climate and how to be successful.
